Verition Fund Management’s Sage Therapeutics SAGE Stock Holding History

Verition Fund Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,000	Closed	-$1.4M	–	1331
2019 Q3	$1.4M	Buy	+10,000	New	+$1.67M	0.04%	333

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Verition Fund Management's SAGE Position: Q3 2025 in Review

Verition Fund Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 184,445 shares — an estimated $1.68M sold.

Verition Fund Management first reported a position in SAGE in Q1 2018 and held it in 18 quarters. The position peaked at $6.54M in Q2 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Verition Fund Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Verition Fund Management sold 184,445 Sage Therapeutics shares in Q3 2025, an estimated $1.68M.
Verition Fund Management first reported a position in Sage Therapeutics in Q1 2018 and held it in 18 quarters.
Verition Fund Management's Sage Therapeutics position peaked at $6.54M in Q2 2023.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.